Biologics manufacturing market forecast to hit $106 billion by 2030

Nov. 20, 2026
Biologics manufacturing market forecast to hit $106 billion by 2030
By AI, Created 13:30 UTC, Nov 20, 2026, AGP -

The biologics manufacturing market is projected to reach $106.08 billion by 2030, up from $42.04 billion in 2025, as demand grows for advanced therapies, biosimilars and personalized medicine. North America led the market in 2025, while Asia-Pacific is expected to post the fastest growth.

Why it matters: - Biologics manufacturing is becoming more central to drug development as demand rises for targeted treatments for cancer, diabetes and autoimmune disease. - The market’s projected 20.3% CAGR through 2030 signals continued investment in capacity, technology and supply chains for biologic medicines.

What happened: - The biologics manufacturing market reached $42.04 billion in 2025 and is projected to rise to $50.69 billion in 2026. - The market is forecast to reach $106.08 billion by 2030. - The Business Research Company published the forecast in its Biologics Manufacturing Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035.

The details: - The report says historical growth was driven by broader use of recombinant protein therapies, early adoption of mammalian cell culture, higher vaccine production capacity, more outsourcing and advances in purification. - Future growth is expected to come from demand for personalized biologic treatments, investment in flexible manufacturing technologies, expansion of biosimilar development, wider use of digital bioprocessing tools and lower-cost large-scale production methods. - Single-use bioprocessing systems are gaining adoption because they improve flexibility and reduce contamination risk. - Continuous biomanufacturing is expanding as a way to improve efficiency and consistency. - Demand is rising for large-volume monoclonal antibody production. - Modular biologics manufacturing facilities are spreading because they can be set up faster and scaled more easily. - Advanced process control systems are being integrated more deeply to improve precision and product quality. - Biologics manufacturing uses living organisms or their components to produce medicines. - The process includes growing genetically engineered cells or microbes in bioreactors, then purifying the products through filtration and chromatography. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, and updated graphics and tables. - A free sample of the report is available here. - The full report is available here.

Between the lines: - The market outlook reflects a shift from traditional batch production toward more flexible, automated and scalable manufacturing models. - The chronic disease burden is a major demand driver because biologics are increasingly used for long-term treatment of complex conditions. - The report cites UK National Health Service data showing 3,615,330 patients were diagnosed with non-diabetic hyperglycemia or pre-diabetes in 2023, up 18% from 3,065,825 in 2022. - North America held the largest share of the market in 2025, but Asia-Pacific is expected to grow fastest during the forecast period.

What's next: - Biologics manufacturers are likely to keep investing in single-use systems, continuous processing and modular facilities to scale output more efficiently. - The market’s fastest growth may come from regions that can combine lower-cost manufacturing with rising demand for biosimilars and advanced therapies. - The Business Research Company is positioning the report as a tool for companies tracking market sizing, hotspots and technology shifts.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

Culture Zone! UK

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Culture Zone! UK

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.